These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26168132)

  • 1. HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
    Yin T; He S; Shen G; Wang Y
    Oncol Res; 2014; 22(3):139-45. PubMed ID: 26168132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
    Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment.
    Burkitt K; Chun SY; Dang DT; Dang LH
    Mol Cancer Ther; 2009 May; 8(5):1148-56. PubMed ID: 19435875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
    Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
    Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis.
    Lee K; Agrawal V; Kim K; Kim J; Park H; Lee S; Kim YM; Suh YG; Kwon YG
    Biochem Biophys Res Commun; 2014 Aug; 450(4):1320-6. PubMed ID: 25003323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
    Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.
    Diaz R; Nguewa PA; Redrado M; Manrique I; Calvo A
    Prostate; 2015 Aug; 75(11):1137-49. PubMed ID: 25893276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib.
    Rini BI
    Expert Opin Pharmacother; 2007 Oct; 8(14):2359-69. PubMed ID: 17927489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
    Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
    Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
    Nguyen L; Fifis T; Christophi C
    BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
    Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
    BMC Cancer; 2017 Jun; 17(1):411. PubMed ID: 28606060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
    Wu CL; Ping SY; Yu CP; Yu DS
    Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model.
    Mousseau Y; Mollard S; Faucher-Durand K; Richard L; Nizou A; Cook-Moreau J; Baaj Y; Qiu H; Plainard X; Fourcade L; Funalot B; Sturtz FG
    Breast Cancer Res Treat; 2012 Jul; 134(1):31-40. PubMed ID: 22160641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
    Czabanka M; Vinci M; Heppner F; Ullrich A; Vajkoczy P
    Int J Cancer; 2009 Mar; 124(6):1293-300. PubMed ID: 19101989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.